SCHEMBL7500978

SCHEMBL7500978

O=C(/C=C/c1ncc[nH]1)c1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 2/20 0.53
MAPT P10636 7/20 0.49
KMT2A Q03164 6/20 0.49
RAB9A P51151 5/20 0.49
MAOB P27338 4/20 0.49
MEN1 O00255 3/20 0.49
MAOA P21397 2/20 0.49
CYP3A4 P08684 2/20 0.49
HSPD1 P10809 2/20 0.49
HSPE1 P61604 2/20 0.49
ALDH2 P05091 1/20 0.49
CYP19A1 P11511 1/20 0.49
CYP1B1 Q16678 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
POLB P06746 2/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
CHRNA7 P36544 1/20 0.46
CXCL12 P48061 1/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7500993 1.00 F3 (0.53) F3MAPTKMT2ARAB9AMAOB
SCHEMBL7501747 0.88 KDM4E (0.51) F3MAPTKMT2ARAB9AMAOB
SCHEMBL7501752 0.88 KDM4E (0.51) F3MAPTKMT2ARAB9AMAOB
SCHEMBL7501713 0.86 CYP1B1 (0.50) MAPTKMT2ARAB9AMAOBMEN1
SCHEMBL7503648 0.86 SMN1; SMN2 (0.56) MAPTMAOBMAOACYP1B1ALDH1A1
SCHEMBL3041751 0.86 CXCL12 (0.40) F3MAPTKMT2ARAB9ACYP3A4
SCHEMBL7503643 0.86 SMN1; SMN2 (0.56) MAPTMAOBMAOACYP1B1ALDH1A1
SCHEMBL7503829 0.86 CYP1B1 (0.50) MAPTRAB9AMAOBMAOACYP1B1
SCHEMBL3041754 0.86 CXCL12 (0.40) F3MAPTKMT2ARAB9ACYP3A4
SCHEMBL7503832 0.86 CYP1B1 (0.50) MAPTRAB9AMAOBMAOACYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344001-B2 Azolylacryloyl derivatives as therapeutic agents for sickle cell disease VIRGINIA COMMONWEALTH UNIVERSITY (US) 2019-07-09 US disclosed
US-10344001-B2 Azolylacryloyl derivatives as therapeutic agents for sickle cell disease VIRGINIA COMMONWEALTH UNIVERSITY (US) 2019-07-09 US disclosed
US-20180282287-A1 AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2018-10-04 US disclosed
EP-0924202-B1 Imidazole derivative and medicine comprising the same as active ingredient SSP CO LTD (JP) 2002-05-29 EP disclosed
US-6071943-A IMMUNOMODULATORS WHICH SUPPRESS SPECIFIC CYTOKINES, FOR AUTOIMMUNE DISEASES SSP CO. LTD. (JP) 2000-06-06 US disclosed
EP-0924202-A1 Imidazole derivative and medicine comprising the same as active ingredient SSP Co., Ltd. (JP) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344001-B2 Azolylacryloyl derivatives as therapeutic agents for sickle cell disease HBG1, HIF1AN, TNNI3 F3 1374/4885MAPT 2718/4885KMT2A 717/4885
US-20180282287-A1 AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE HBG1, HIF1AN, TNNI3 F3 1374/4885MAPT 2718/4885KMT2A 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.